Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 07, 2020 Filed Jan 10, 2020 02:28 UTC |
Puche LuisaChief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001731122-20-000033 · ownership.xml · derivative · entry 2 Puche Luisa · CIK 0001768468 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 5,000 shares Expires 2029-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2020 Filed Jan 10, 2020 02:28 UTC |
Puche LuisaChief Financial Officer
|
Exercise / conversionCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001731122-20-000033 · ownership.xml · nonDerivative · entry 1 Puche Luisa · CIK 0001768468 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 22, 2019 Filed Aug 26, 2019 18:55 UTC |
Sandler Carl ForestDirector
|
GrantOption to purchase shares of common stock · Derivative | 8,248 | $0.00 Strike: $7.10 | $0.00 |
DisclosureSEC source: 0001731122-19-000522 · ownership.xml · derivative · entry 1 Sandler Carl Forest Jr · CIK 0001734560 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,248 Underlying: Common stock · 8,248 shares Expires 2029-02-25 Read SEC document |
| August 22, 2019 Filed Aug 26, 2019 22:51 UTC |
D An EvelynDirector
|
GrantOption to Purchase Common Stock · Derivative | 9,173 | $0.00 Strike: $6.25 | $0.00 |
DisclosureSEC source: 0001731122-19-000518 · ownership.xml · derivative · entry 1 D An Evelyn · CIK 0001325168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,173 Underlying: Common Stock · 9,173 shares Expires 2029-03-03 F1 · security: On August 22, 2019, Ms. D'An was granted an option to purchase 9,173 shares of common stock of Enochian Biosciences, Inc., said option to vest on December 10, 2019. Read SEC document |
| August 22, 2019 Filed Aug 26, 2019 20:47 UTC |
SAPIRSTEIN JAMESDirector
|
GrantOption to Purchase Common Stock · Derivative | 9,173 | $0.00 Strike: $6.25 | $0.00 |
DisclosureSEC source: 0001731122-19-000516 · ownership.xml · derivative · entry 1 SAPIRSTEIN JAMES · CIK 0001559509 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,173 Underlying: Common Stock · 9,173 shares Expires 2029-03-03 F1 · security: On August 22, 2019, Mr. Sapirstein was granted an option to purchase 9,173 shares of common stock of Enochian Biosciences, Inc., said option to vest on December 10, 2019. Read SEC document |
| August 22, 2019 Filed Aug 26, 2019 22:57 UTC |
Sindlev ReneDirector · 10% owner
|
GrantOption to purchase shares of common stock · Derivative | 3,346 | $0.00 Strike: $4.90 | $0.00 |
DisclosureSEC source: 0001731122-19-000524 · ownership.xml · derivative · entry 1 Sindlev Rene · CIK 0001709513 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,346 Underlying: Common Stock · 3,346 shares Expires 2029-07-27 F1 · security: On August 22, 2019, Mr. Sindlev was granted an option to purchase 3,346 shares of the issuer's common stock, vesting on December 10, 2019. Read SEC document |
| August 22, 2019 Filed Aug 26, 2019 22:53 UTC |
Gronfeldt-Sorensen HenrikDirector
|
GrantOption to purchase common stock · Derivative | 7,759 | $0.00 Strike: $5.80 | $0.00 |
DisclosureSEC source: 0001731122-19-000520 · ownership.xml · derivative · entry 1 Gronfeldt-Sorensen Henrik · CIK 0001720024 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,759 Underlying: Common stock · 7,759 shares Expires 2028-10-06 F1 · security: On August 22, 2019, Mr. Gronfeldt-Sorensen was granted an option to purchase 7,759 shares of Issuer's common stock, vesting on December 10, 2019. Read SEC document |
| July 30, 2019 Filed Aug 1, 2019 21:28 UTC |
Sandler Carl ForestDirector · 10% owner
William Anderson Wittekind10% owner
|
OtherCommon Stock | 3,631,234 | $0.00 | $0.00 |
DisclosureSEC source: 0001731122-19-000425 · ownership.xml · nonDerivative · entry 1 Sandler Carl Forest Jr · CIK 0001734560 · Director · 10% owner William Anderson Wittekind · CIK 0001753085 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Weird Science, LLC Disclosed balance after: 22,445,397 F1 · security: On July 30, 2019, Weird Science, LLC received 3,631,234 shares of common stock pursuant to a contractual right to receive shares upon the exercise of warrants by warrant holders of the Issuer. Mr. Sandler and W. Anderson Wittekind are each managers of Weird Science and share investment control over the shares held by Weird Science, LLC. Read SEC document |
| July 30, 2019 Filed Aug 2, 2019 01:26 UTC |
Sindlev ReneDirector · 10% owner
|
OtherWarrant (right to buy) · Derivative | 3,092,307 | $1.30 Strike: $1.30 | $4,019,999.10 |
DisclosureSEC source: 0001731122-19-000423 · ownership.xml · derivative · entry 2 Sindlev Rene · CIK 0001709513 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By RS Bio ApS Disclosed balance after: 0 Underlying: Common Stock · 3,092,307 shares Expires 2022-04-21 Read SEC document |
| July 30, 2019 Filed Aug 2, 2019 01:26 UTC |
Sindlev ReneDirector · 10% owner
|
OtherCommon Stock | 3,092,307 | $1.30 | $4,019,999.10 |
DisclosureSEC source: 0001731122-19-000423 · ownership.xml · nonDerivative · entry 1 Sindlev Rene · CIK 0001709513 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By RS Bio ApS Disclosed balance after: 9,668,351 F1 · security: On July 30, 2019, the conditions necessary for the exercise of a warrant to purchase 3,092,307 shares of Issuer's common stock for $1.30 per share pursuant to a notice of exercise dated June 27, 2019 were satisfied and the reporting person was issued 3,092,307 shares of Issuer's common stock. Read SEC document |
| July 30, 2019 Filed Aug 2, 2019 01:28 UTC |
Dybul MarkDirector · Executive Vice Chair
|
OtherCommon Stock | 10,680 | $0.00 | $0.00 |
DisclosureSEC source: 0001731122-19-000424 · ownership.xml · nonDerivative · entry 1 Dybul Mark · CIK 0001734805 · Director · Executive Vice Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,016 F1 · security: On July 30, 2019, Mark Dybul, M.D. received 10,680 shares of common stock pursuant to a contractual right to receive shares upon the exercise of warrants by warrant holders of the Issuer. Read SEC document |
| July 30, 2019 Filed Feb 7, 2023 00:24 UTC |
Weird Science LLC10% owner
|
OtherCommon Stock | 3,631,234 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001214659-23-001671 · marketforms-58228.xml · nonDerivative · entry 3 Weird Science LLC · CIK 0001955760 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,445,397 F2 · kind: Shares were received by the Reporting Person as Earnout Stock pursuant to the Merger Agreement. The Reporting Person's right to the Earnout Stock became fixed and irrevocable on February 16, 2018, the date of the closing under the Merger Agreement. F2 · price: Shares were received by the Reporting Person as Earnout Stock pursuant to the Merger Agreement. The Reporting Person's right to the Earnout Stock became fixed and irrevocable on February 16, 2018, the date of the closing under the Merger Agreement. Read SEC document |
| June 09, 2019 Filed Dec 21, 2021 00:01 UTC |
Puche LuisaChief Financial Officer
|
OtherRestricted Stock Units · Derivative | 15,000 | $6.15 Strike: $6.15 | $92,250.00 |
DisclosureSEC source: 0001731122-21-002163 · ownership.xml · derivative · entry 2 Puche Luisa · CIK 0001768468 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2029-06-09 F3 · derivative.exercise_date: Reflects the decision of the Enochian BioSciences Inc. board of directors to void and rescind, nunc pro tunc, the grant of 15,000 RSUs previously approved on June 9, 2019, under the Issuer's 2019 Equity Incentive Plan. As of the date of this Form 4, 10,000 RSUs had vested; the reporting person has agreed to surrender the 10,000 shares of common stock underlying the RSUs to Enochian BioSciences Inc. for cancellation. Read SEC document |
| June 06, 2019 Filed Jun 21, 2019 20:36 UTC |
Puche LuisaChief Financial Officer
|
GrantRestricted Stock Units · Derivative | 15,000 | $6.15 Strike: $6.15 | $92,250.00 |
DisclosureSEC source: 0001731122-19-000353 · ownership.xml · derivative · entry 2 Puche Luisa · CIK 0001768468 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-01-07 F2 · derivative.exercise_date: On June 6, 2019, Ms. Puche was granted fifteen thousand (15,000) restricted stock units, vesting in equal amounts annually over three years from January 7, 2019, the date of her appointment as Chief Financial Officer of Enochian Biosciences, Inc. Read SEC document |
| June 06, 2019 Filed Jun 21, 2019 20:36 UTC |
Puche LuisaChief Financial Officer
|
GrantOption to Purchase Common Stock · Derivative | 60,000 | $6.15 Strike: $6.15 | $369,000.00 |
DisclosureSEC source: 0001731122-19-000353 · ownership.xml · derivative · entry 1 Puche Luisa · CIK 0001768468 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2029-01-07 F1 · derivative.exercise_date: On June 6, 2019, Ms. Puche was granted options to purchase sixty thousand (60,000) shares of the Company's common stock vesting in equal amounts annually over three years from January 7, 2019, the date of her appointment as Chief Financial Officer of Enochian Biosciences, Inc., pursuant to the Company's 2014 Equity Incentive Plan. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 18:26 UTC |
Sindlev ReneDirector · 10% owner
|
PurchaseCommon Stock | 31,500 | $6.70 | $211,050.00 |
DisclosureSEC source: 0001731122-19-000310 · ownership.xml · nonDerivative · entry 1 Sindlev Rene · CIK 0001709513 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By RS Bio ApS Disclosed balance after: 6,576,044 Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 18:07 UTC |
Sindlev ReneDirector · 10% owner
|
PurchaseCommon Stock | 40,000 | $6.70 | $268,000.00 |
DisclosureSEC source: 0001731122-19-000305 · ownership.xml · nonDerivative · entry 1 Sindlev Rene · CIK 0001709513 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By RS Bio ApS Disclosed balance after: 6,544,544 Read SEC document |
| May 29, 2019 Filed Jun 5, 2019 18:06 UTC |
Sindlev ReneDirector · 10% owner
|
PurchaseCommon Stock | 20,000 | $6.60 | $132,000.00 |
DisclosureSEC source: 0001731122-19-000304 · ownership.xml · nonDerivative · entry 1 Sindlev Rene · CIK 0001709513 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By RS Bio ApS Disclosed balance after: 6,504,544 Read SEC document |
| May 28, 2019 Filed May 30, 2019 20:05 UTC |
Sindlev ReneDirector · 10% owner
|
PurchaseCommon Stock | 36,200 | $6.61 | $239,282.00 |
DisclosureSEC source: 0001731122-19-000294 · ownership.xml · nonDerivative · entry 1 Sindlev Rene · CIK 0001709513 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By RS Bio ApS Disclosed balance after: 6,479,530 Read SEC document |
| May 28, 2019 Filed Jun 5, 2019 18:08 UTC Amendment |
Sindlev ReneDirector · 10% owner
|
PurchaseCommon Stock | 36,200 | $6.61 | $239,282.00 |
DisclosureSEC source: 0001731122-19-000306 · ownership.xml · nonDerivative · entry 1 Sindlev Rene · CIK 0001709513 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By RS Bio ApS Disclosed balance after: 6,484,544 Read SEC document |
| May 24, 2019 Filed Jun 5, 2019 18:05 UTC |
Sindlev ReneDirector · 10% owner
|
PurchaseCommon Stock | 5,014 | $6.25 | $31,337.50 |
DisclosureSEC source: 0001731122-19-000303 · ownership.xml · nonDerivative · entry 1 Sindlev Rene · CIK 0001709513 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By RS Bio ApS Disclosed balance after: 6,448,344 Read SEC document |
| May 22, 2019 Filed May 24, 2019 19:39 UTC |
Sindlev ReneDirector · 10% owner
|
PurchaseCommon Stock | 500 | $5.76 | $2,880.00 |
DisclosureSEC source: 0001731122-19-000283 · ownership.xml · nonDerivative · entry 1 Sindlev Rene · CIK 0001709513 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By RS Bio ApS Disclosed balance after: 6,443,330 Read SEC document |
| May 21, 2019 Filed May 23, 2019 21:39 UTC |
Sindlev ReneDirector · 10% owner
|
PurchaseCommon Stock | 20,000 | $5.75 | $115,000.00 |
DisclosureSEC source: 0001731122-19-000280 · ownership.xml · nonDerivative · entry 1 Sindlev Rene · CIK 0001709513 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By RS Bio ApS Disclosed balance after: 6,442,830 Read SEC document |
| January 10, 2019 Filed Jan 11, 2019 22:37 UTC |
Gronfeldt-Sorensen HenrikDirector
|
OtherWarrant to purchase common stock · Derivative | 50,000 | $2.00 Strike: $2.00 | $100,000.00 |
DisclosureSEC source: 0001731122-19-000018 · ownership.xml · derivative · entry 2 Gronfeldt-Sorensen Henrik · CIK 0001720024 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Greenfield Holding ApS Disclosed balance after: 0 Underlying: Common stock · 50,000 shares Expires 2019-12-31 Read SEC document |
| January 10, 2019 Filed Jan 11, 2019 22:37 UTC |
Gronfeldt-Sorensen HenrikDirector
|
PurchaseCommon Stock | 50,000 | $2.00 | $100,000.00 |
DisclosureSEC source: 0001731122-19-000018 · ownership.xml · nonDerivative · entry 1 Gronfeldt-Sorensen Henrik · CIK 0001720024 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Greenfield Holding ApS Disclosed balance after: 50,000 F1 · ownership.nature: Greenfield Holding ApS is a Danish limited company controlled by Mr. Gronfeldt-Sorensen. Read SEC document |
| December 31, 2018 Filed Jan 3, 2019 21:43 UTC |
Sandler Carl ForestDirector · 10% owner
William Anderson WittekindDirector · 10% owner
|
OtherCommon Stock | 1,268,880 | $0.00 | $0.00 |
DisclosureSEC source: 0001731122-19-000007 · ownership.xml · nonDerivative · entry 1 Sandler Carl Forest Jr · CIK 0001734560 · Director · 10% owner William Anderson Wittekind · CIK 0001753085 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Weird Science, LLC Disclosed balance after: 18,814,163 F1 · security: On December 31, 2018, Weird Science, LLC received 1,268,880 shares of common stock pursuant to a contractual right to receive shares upon the exercise of warrants by RS Bio ApS. Mr. Sandler and W. Anderson Wittekind are each managers of Weird Science and share investment control over the shares held by Weird Science, LLC. Read SEC document |
| December 31, 2018 Filed Jan 4, 2019 02:44 UTC |
Dybul MarkDirector · Executive Vice Chair
|
OtherCommon Stock | 3,732 | $0.00 | $0.00 |
DisclosureSEC source: 0001731122-19-000008 · ownership.xml · nonDerivative · entry 1 Dybul Mark · CIK 0001734805 · Director · Executive Vice Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,336 F1 · security: On December 31, 2018, Mark Dybul received 3,732 shares of common stock pursuant to a contractual right to receive shares upon the exercise of warrants by RS Bio ApS. Read SEC document |
| December 31, 2018 Filed Feb 7, 2023 00:24 UTC |
Weird Science LLC10% owner
|
OtherCommon Stock | 1,268,880 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001214659-23-001671 · marketforms-58228.xml · nonDerivative · entry 2 Weird Science LLC · CIK 0001955760 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,814,163 F2 · kind: Shares were received by the Reporting Person as Earnout Stock pursuant to the Merger Agreement. The Reporting Person's right to the Earnout Stock became fixed and irrevocable on February 16, 2018, the date of the closing under the Merger Agreement. F2 · price: Shares were received by the Reporting Person as Earnout Stock pursuant to the Merger Agreement. The Reporting Person's right to the Earnout Stock became fixed and irrevocable on February 16, 2018, the date of the closing under the Merger Agreement. Read SEC document |
| December 27, 2018 Filed Dec 29, 2018 00:11 UTC |
Sindlev ReneDirector · 10% owner
|
OtherWarrant to Purchase Common Stock · Derivative | 1,307,693 | $1.30 Strike: $1.30 | $1,700,000.90 |
DisclosureSEC source: 0001731122-18-000190 · ownership.xml · derivative · entry 3 Sindlev Rene · CIK 0001709513 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By RS Bio ApS Disclosed balance after: 3,092,307 Underlying: Common Stock · 1,307,693 shares Expires 2022-04-21 F1 · ownership.nature: ApS assigned its holdings in Enochian Biosciences, Inc. to RS Bio ApS. Both entities are wholly owned by Rene Sindlev. Read SEC document |
| December 27, 2018 Filed Dec 29, 2018 00:11 UTC |
Sindlev ReneDirector · 10% owner
|
OtherCommon Stock | 1,307,693 | $1.30 | $1,700,000.90 |
DisclosureSEC source: 0001731122-18-000190 · ownership.xml · nonDerivative · entry 2 Sindlev Rene · CIK 0001709513 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By RS Bio ApS Disclosed balance after: 6,422,830 Read SEC document |
| December 27, 2018 Filed Dec 29, 2018 00:11 UTC |
Sindlev ReneDirector · 10% owner
|
PurchaseCommon Stock | 92,968 | $8.00 | $743,744.00 |
DisclosureSEC source: 0001731122-18-000190 · ownership.xml · nonDerivative · entry 1 Sindlev Rene · CIK 0001709513 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By RS Bio ApS Disclosed balance after: 5,115,137 Read SEC document |
| November 21, 2018 Filed Dec 7, 2018 18:46 UTC |
Dybul MarkDirector
|
GrantOption to Purchase Common Stock · Derivative | 300,000 | $6.50 Strike: $6.50 | $1,950,000.00 |
DisclosureSEC source: 0001731122-18-000180 · ownership.xml · derivative · entry 1 Dybul Mark · CIK 0001734805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 312,834 Underlying: Common Stock · 300,000 shares Expires 2018-11-21 Read SEC document |
| September 19, 2018 Filed Sep 27, 2018 10:42 UTC |
D An EvelynDirector
|
GrantOption to Purchase Common Stock · Derivative | 5,226 | $5.74 Strike: $5.74 | $29,997.24 |
DisclosureSEC source: 0001731122-18-000083 · ownership.xml · derivative · entry 1 D An Evelyn · CIK 0001325168 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,770 Underlying: Common Stock · 5,226 shares Expires 2028-09-19 F1 · security: On September 19, 2018, Ms. D'An was granted an option to purchase shares of common stock of Enochian Biosciences, Inc. valued at $30,000, said option to vest on the anniversary date of Ms. D'An's appointment as director of Enochian, exercisable at the closing market price per share on the date of the grant. Read SEC document |
| September 19, 2018 Filed Sep 27, 2018 17:04 UTC |
Dybul MarkDirector
|
GrantOption to Purchase Common Stock · Derivative | 5,226 | $5.74 Strike: $5.74 | $29,997.24 |
DisclosureSEC source: 0001731122-18-000087 · ownership.xml · derivative · entry 1 Dybul Mark · CIK 0001734805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,834 Underlying: Common Stock · 5,226 shares Expires 2028-09-19 F1 · security: On September 19, 2018, Dr. Dybul was granted an option to purchase shares of common stock of Enochian Biosciences, Inc. valued at $30,000, said option to vest on the anniversary date of Dr. Dybul's appointment as director of Enochian, exercisable at the closing market price per share on the date of the grant. Read SEC document |
| September 19, 2018 Filed Sep 27, 2018 10:43 UTC |
SAPIRSTEIN JAMESDirector
|
GrantOption to Purchase Common Stock · Derivative | 5,226 | $5.74 Strike: $5.74 | $29,997.24 |
DisclosureSEC source: 0001731122-18-000085 · ownership.xml · derivative · entry 1 SAPIRSTEIN JAMES · CIK 0001559509 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,770 Underlying: Common Stock · 5,226 shares Expires 2028-09-19 F1 · security: On September 19, 2018, Mr. Sapirstein was granted an option to purchase shares of common stock of Enochian Biosciences, Inc. valued at $30,000, said option to vest on the anniversary date of Mr. Sapirstein's appointment as director of Enochian, exercisable at the closing market price per share on the date of the grant. Read SEC document |
| September 19, 2018 Filed Nov 8, 2018 02:12 UTC |
Sindlev ReneDirector · 10% owner
|
GrantOption to Purchase Common Stock · Derivative | 7,840 | $5.74 Strike: $5.74 | $45,001.60 |
DisclosureSEC source: 0001731122-18-000139 · ownership.xml · derivative · entry 1 Sindlev Rene · CIK 0001709513 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,840 Underlying: Common Stock · 7,840 shares Expires 2028-09-19 Read SEC document |
| May 24, 2018 Filed Jun 4, 2018 16:50 UTC |
Leire, Eric Jean MarieChief Executive Officer
|
PurchaseCommon Stock | 500 | $5.25 | $2,625.00 |
DisclosureSEC source: 0001731122-18-000017 · e1099_form4.xml · nonDerivative · entry 5 Leire, Eric Jean Marie · CIK 0001600390 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,246 Read SEC document |
| May 24, 2018 Filed Jun 4, 2018 16:50 UTC |
Leire, Eric Jean MarieChief Executive Officer
|
PurchaseCommon Stock | 200 | $5.33 | $1,066.00 |
DisclosureSEC source: 0001731122-18-000017 · e1099_form4.xml · nonDerivative · entry 4 Leire, Eric Jean Marie · CIK 0001600390 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,746 Read SEC document |
| May 22, 2018 Filed Jun 4, 2018 16:50 UTC |
Leire, Eric Jean MarieChief Executive Officer
|
PurchaseCommon Stock | 300 | $5.25 | $1,575.00 |
DisclosureSEC source: 0001731122-18-000017 · e1099_form4.xml · nonDerivative · entry 3 Leire, Eric Jean Marie · CIK 0001600390 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,546 Read SEC document |
| May 21, 2018 Filed Nov 8, 2018 02:13 UTC |
Sindlev ReneDirector · 10% owner
|
PurchaseCommon Stock | 1,300 | $5.38 | $6,994.00 |
DisclosureSEC source: 0001731122-18-000140 · ownership.xml · nonDerivative · entry 1 Sindlev Rene · CIK 0001709513 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By RS Group ApS Disclosed balance after: 5,022,169 F1 · ownership.nature: On May 21, 2018, RS Group ApS, an entity controlled by Mr. Sindlev, purchased 1,300 shares of common stock of Enochian Biosciences, Inc. in an open market transaction. RS Group ApS subsequently transferred all of its shares to RS Biopharma ApS, an entity controlled by Mr. Sindlev. Read SEC document |
| May 17, 2018 Filed Jun 4, 2018 16:50 UTC |
Leire, Eric Jean MarieChief Executive Officer
|
PurchaseCommon Stock | 754 | $5.40 | $4,071.60 |
DisclosureSEC source: 0001731122-18-000017 · e1099_form4.xml · nonDerivative · entry 2 Leire, Eric Jean Marie · CIK 0001600390 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,246 Read SEC document |
| May 16, 2018 Filed Jun 4, 2018 16:50 UTC |
Leire, Eric Jean MarieChief Executive Officer
|
PurchaseCommon Stock | 190 | $5.50 | $1,045.00 |
DisclosureSEC source: 0001731122-18-000017 · e1099_form4.xml · nonDerivative · entry 1 Leire, Eric Jean Marie · CIK 0001600390 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,492 Read SEC document |
| February 21, 2018 Filed Feb 6, 2023 19:26 UTC |
William Anderson Wittekind10% owner
|
SaleCommon Stock | 200,000 | $8.00 | $1,600,000.00 |
DisclosureSEC source: 0001214659-23-001672 · marketforms-58242.xml · nonDerivative · entry 1 William Anderson Wittekind · CIK 0001753085 · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Weird Science LLC Disclosed balance after: 17,545,283 F1 · shares: Shares were sold by Gumrukcu Health, LLC, of which the Reporting Person is a minority managing member. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein. F2 · balance_after: These shares were issued to Weird Science LLC as merger consideration in exchange for common stock of Enochian BioPharma, Inc. (the "Target"), which the Issuer acquired by merger on February 16, 2018 pursuant to an Agreement and Plan of Merger dated January 12, 2018 by and among the Issuer, the Issuer's Merger Sub, the Target and Weird Science LLC (the "Merger Agreement"). F3 · ownership.nature: The Reporting Person is a manager of Weird Science LLC. Read SEC document |
| February 16, 2018 Filed Nov 8, 2018 02:13 UTC |
Sindlev ReneDirector · 10% owner
|
OtherWarrant to Purchase Common Stock · Derivative | 250,000 | $2.00 Strike: $2.00 | $500,000.00 |
DisclosureSEC source: 0001731122-18-000141 · ownership.xml · derivative · entry 4 Sindlev Rene · CIK 0001709513 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By RS Group ApS Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires 2019-12-31 Read SEC document |
| February 16, 2018 Filed Nov 8, 2018 02:13 UTC |
Sindlev ReneDirector · 10% owner
|
OtherWarrant to Purchase Common Stock · Derivative | 1,000,000 | $1.30 Strike: $1.30 | $1,300,000.00 |
DisclosureSEC source: 0001731122-18-000141 · ownership.xml · derivative · entry 3 Sindlev Rene · CIK 0001709513 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By RS Group ApS Disclosed balance after: 4,400,000 Underlying: Common Stock · 1,000,000 shares Expires 2022-04-21 Read SEC document |
| February 16, 2018 Filed Nov 8, 2018 02:13 UTC |
Sindlev ReneDirector · 10% owner
|
OtherCommon Stock | 250,000 | $2.00 | $500,000.00 |
DisclosureSEC source: 0001731122-18-000141 · ownership.xml · nonDerivative · entry 2 Sindlev Rene · CIK 0001709513 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By RS Group ApS Disclosed balance after: 5,020,869 Read SEC document |
| February 16, 2018 Filed Nov 8, 2018 02:13 UTC |
Sindlev ReneDirector · 10% owner
|
OtherCommon Stock | 1,000,000 | $1.30 | $1,300,000.00 |
DisclosureSEC source: 0001731122-18-000141 · ownership.xml · nonDerivative · entry 1 Sindlev Rene · CIK 0001709513 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By RS Group ApS Disclosed balance after: 4,770,869 Read SEC document |
| February 16, 2018 Filed Feb 7, 2023 00:24 UTC |
Weird Science LLC10% owner
|
OtherCommon Stock | 17,545,283 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001214659-23-001671 · marketforms-58228.xml · nonDerivative · entry 1 Weird Science LLC · CIK 0001955760 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,545,283 F1 · kind: The Reporting Person received these shares as merger consideration in exchange for the Reporting Person's common stock of Enochian BioPharma, Inc., which the Issuer acquired by merger on February 16, 2018. In addition to such shares, the Agreement and Plan of Merger governing the merger (the "Merger Agreement") provides that upon the exercise or conversion of options and warrants to purchase shares of the Issuer's common stock that were outstanding as of the closing of the merger, the Issuer will issue a like number of shares of Common Stock (referred to as "Earn-Out Stock") to the former stockholders of Enochian BioPharma, Inc., including the Reporting Person, on a pro rata basis. The Reporting Person's right to receive additional shares of the Issuer's common stock as Earn-Out Stock became fixed and irrevocable on February 16, 2018, the closing date of the merger. F1 · price: The Reporting Person received these shares as merger consideration in exchange for the Reporting Person's common stock of Enochian BioPharma, Inc., which the Issuer acquired by merger on February 16, 2018. In addition to such shares, the Agreement and Plan of Merger governing the merger (the "Merger Agreement") provides that upon the exercise or conversion of options and warrants to purchase shares of the Issuer's common stock that were outstanding as of the closing of the merger, the Issuer will issue a like number of shares of Common Stock (referred to as "Earn-Out Stock") to the former stockholders of Enochian BioPharma, Inc., including the Reporting Person, on a pro rata basis. The Reporting Person's right to receive additional shares of the Issuer's common stock as Earn-Out Stock became fixed and irrevocable on February 16, 2018, the closing date of the merger. Read SEC document |
| October 17, 2017 Filed Nov 8, 2018 02:13 UTC |
Sindlev ReneDirector · 10% owner
|
PurchaseWarrant to Purchase Common Stock · Derivative | 250,000 | $2.00 Strike: $2.00 | $500,000.00 |
DisclosureSEC source: 0001731122-18-000142 · ownership.xml · derivative · entry 1 Sindlev Rene · CIK 0001709513 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By RS Group ApS Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2019-12-31 Read SEC document |
| October 13, 2017 Filed Oct 19, 2017 22:51 UTC |
Sindlev ReneDirector · 10% owner
|
PurchaseWarrants to purchase shares of common stock · Derivative | 250,000 | $2.00 Strike: $2.00 | $500,000.00 |
DisclosureSEC source: 0001213900-17-010746 · f4101317sindlev_dandrit.xml · derivative · entry 1 Sindlev Rene · CIK 0001709513 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 5,650,000 Underlying: Common Stock · 250,000 shares Expires 2019-12-31 F1 · security: On October 13, 2017, RS Group ApS, an entity controlled by Mr. Sindlev, purchased 250,000 warrants to purchase shares of common stock of Dandrit Biotech USA, Inc. in a private transaction. F1 · ownership.nature: On October 13, 2017, RS Group ApS, an entity controlled by Mr. Sindlev, purchased 250,000 warrants to purchase shares of common stock of Dandrit Biotech USA, Inc. in a private transaction. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.